CCCC
USDC4 Therapeutics Inc. Common Stock
实时价格
价格图表
关键指标
市场指标
开盘价
$2.350
最高价
$2.420
最低价
$2.290
成交量
1.58M
公司基本面
市值
225.3M
所属行业
生物技术
国家/地区
United States
交易统计
平均成交量
1.92M
交易所
NMS
货币
USD
52周价格范围
相关新闻
Wells Fargo Maintains Overweight on C4 Therapeutics, Raises Price Target to $10
Wells Fargo analyst Derek Archila maintains C4 Therapeutics with a Overweight and raises the price target from $5 to $10.
Stephens & Co. Reiterates Overweight on C4 Therapeutics, Maintains $6 Price Target
Stephens & Co. analyst Sudan Loganathan reiterates C4 Therapeutics with a Overweight and maintains $6 price target.
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple
Barclays Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $8
Barclays analyst Etzer Darout initiates coverage on C4 Therapeutics with a Overweight rating and announces Price Target of $8.
Stephens & Co. Upgrades C4 Therapeutics to Overweight, Raises Price Target to $6
Stephens & Co. analyst Sudan Loganathan upgrades C4 Therapeutics from Equal-Weight to Overweight and raises the price target from $3 to $6.
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development...
C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration
WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced
相关股票
HTLD
Heartland Express Inc.
LASE
Laser Photonics Corporation
PLPC
Preformed Line Products Company
BWBBP
Bridgewater Bancshares Inc. Depositary Shares Each Representing a 1/100th Interest in a Share of 5.875% Non-Cumulative Perpetual Preferred Stock Series A
DRMA
Dermata Therapeutics Inc.
保持更新
设置价格提醒，获取AI分析更新和实时市场新闻。